ArticleLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2017
Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates.
Article in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Association of non-selective β blockers with the development of renal dysfunction in liver cirrhosis: a systematic review and meta-analysis.Annals of medicine · 2024Pooled it
- Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial.Hepatology international · 2024Trial
- Nonselective Beta Blockers Are Beneficial in Patients with Cirrhotic Ascites and Spontaneous Bacterial Peritonitis: A Propensity-Matched Study.Journal of clinical medicine · 2026Article
- Article
- Pharmacological Interventions for Cirrhotic Ascites: From Challenges to Emerging Therapeutic Horizons.Gut and liver · 2024Review
- Impact of beta-blocker usage on delirium in patients with sepsis in ICU: a cross-sectional study.Frontiers in medicine · 2024Article
- B-Blockers in Liver Cirrhosis: A Wonder Drug for Every Stage of Portal Hypertension? A Narrative Review.Biomedicines · 2023Review
- Hepatorenal syndrome: Current concepts and future perspectives.Clinical and molecular hepatology · 2023Review
- Incidence, risk factors and outcomes of acute kidney injury in surgical intensive care unit octogenarians at the Jordan University Hospital.BMC geriatrics · 2023Article
- Use of non-selective B-blockers is safe in hospitalised decompensated cirrhosis patients and exerts a potential anti-inflammatory effect: Data from the ATTIRE trial.EClinicalMedicine · 2023Article
- Nonselective beta-blocker use is associated with increased hepatic encephalopathy-related readmissions in cirrhosis.World journal of clinical cases · 2022Article
- Development and validation of a nomogram for predicting acute kidney injury after orthotopic liver transplantation.Renal failure · 2021Article
- β-blockers in advanced cirrhosis: More friend than enemy.Clinical and molecular hepatology · 2021Review
- Beta-blockers in cirrhosis: Evidence-based indications and limitations.JHEP reports : innovation in hepatology · 2020Review
- Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation.BMC gastroenterology · 2020Article
- Propranolol plus endoscopic ligation for variceal bleeding in patients with significant ascites: Propensity score matching analysis.Medicine · 2020Article
- Current and future pharmacological therapies for managing cirrhosis and its complications.World journal of gastroenterology · 2019Review
- CON ("The window is closed"): In patients with cirrhosis with ascites, the clinical risks of nonselective beta-blocker outweigh the benefits and should NOT be prescribed.Clinical liver disease · 2018Review
- Outcomes of Portal Pressure-Guided Therapy in Decompensated Cirrhosis With Index Variceal Bleed in Asian Cohort.Journal of clinical and experimental hepatologyArticle
Corrections and comments
- Commented on by
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Nonselective beta-blockers (NSBBs) have played an important role in the prevention of portal hypertensive bleeding in patients with cirrhosis. However, recent studies have suggested that NSBBs may be harmful in some patients with end-stage liver disease. The purpose of this article is to evaluate the association between use of NSBB and the incidence of acute kidney injury (AKI). We conducted a nested case-control study in a cohort of liver transplant wait-list registrants. Each patient with AKI was matched to a control by the Model for End-Stage Liver Disease-Na score, age, serum creatinine, and follow-up duration. Out of a total of 2361 wait-list registrants, 205 patients developed AKI after a median follow-up duration of 18.2 months. When compared with matched controls, ascites (79.0% versus 51.7%) and non-Caucasian race (16.6% versus 7.8%) were more common among the cases. The frequency of NSBB use was higher among the cases than controls, albeit insignificantly (45.9% versus 37.1%; P = 0.08). In multivariate analyses, the impact of nonselective beta blockade on the development of AKI was dependent on the presence of ascites: nonselective beta blockade in patients with ascites significantly increased the risk of AKI (hazard ratio [HR], 3.31; 95% confidence interval [CI], 1.57-6.95), whereas in patients without ascites, NSBB use reduced it (HR, 0.19; 95% CI, 0.06-0.60). Potential benefits and harms of a NSBB in terms of AKI depend on the presence of ascites in liver transplant candidates. NSBB therapy in patients with cirrhosis may need to be individualized. Liver Transplantation 23 733-740 2017 AASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.